Similar articles for PMID: 35220251

Year	Number of Results
2016	2
2017	3
2018	6
2019	20
2020	41
2021	49
2022	44
2023	12
2024	1

1

PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer.

Ito T, Okamoto I, Tokashiki K, Sato H, Okada T, Yamashita G, Nagao T, Hirai H, Saigusa N, Tsukahara K. Ito T, et al. Anticancer Res. 2022 Mar;42(3):1547-1554. doi: 10.21873/anticanres.15628. Anticancer Res. 2022. PMID: 35220251

2

Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.

Emancipator K, Huang L, Aurora-Garg D, Bal T, Cohen EEW, Harrington K, Soulières D, Le Tourneau C, Licitra L, Burtness B, Swaby R. Emancipator K, et al. Mod Pathol. 2021 Mar;34(3):532-541. doi: 10.1038/s41379-020-00710-9. Epub 2020 Nov 25. Mod Pathol. 2021. PMID: 33239737 Free article.

3

Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.

Okamoto I, Sato H, Tsukahara K. Okamoto I, et al. Auris Nasus Larynx. 2020 Aug;47(4):676-686. doi: 10.1016/j.anl.2020.04.001. Epub 2020 May 19. Auris Nasus Larynx. 2020. PMID: 32439271

4

Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma.

Okada T, Fushimi C, Matsuki T, Okamoto I, Sato H, Kondo T, Tokashiki K, Kishida T, Ito T, Yamashita G, Aihara Y, Hanyu K, Kushihashi Y, Masubuchi T, Tada Y, Miura K, Harada Y, Momiyama K, Yamashita T, Omura GO, Takahashi H, Oridate N, Tsukahara K. Okada T, et al. Anticancer Res. 2022 Mar;42(3):1607-1613. doi: 10.21873/anticanres.15635. Anticancer Res. 2022. PMID: 35220258

5

Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.

Economopoulou P, Kotsantis I, Papaxoinis G, Gavrielatou N, Anastasiou M, Pantazopoulos A, Kavourakis G, Gkolfinopoulos S, Panayiotides I, Delides A, Psyrri A. Economopoulou P, et al. Oral Oncol. 2020 Dec;111:105013. doi: 10.1016/j.oraloncology.2020.105013. Epub 2020 Sep 23. Oral Oncol. 2020. PMID: 32977184

6

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.

Kim H, Kwon M, Kim B, Jung HA, Sun JM, Lee SH, Park K, Ahn MJ. Kim H, et al. BMC Cancer. 2020 Aug 5;20(1):727. doi: 10.1186/s12885-020-07214-4. BMC Cancer. 2020. PMID: 32758163 Free PMC article.

7

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.

8

Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.

Lee YG, Chang H, Keam B, Chun SH, Park J, Park KU, Shin SH, An HJ, Lee KE, Lee KW, Kim HR, Kim SB, Ahn MJ, Hwang IG. Lee YG, et al. Cancer Res Treat. 2021 Jul;53(3):671-677. doi: 10.4143/crt.2020.824. Epub 2020 Dec 7. Cancer Res Treat. 2021. PMID: 33285051 Free PMC article.

9

Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma.

Okamoto I, Tsukahara K, Sato H. Okamoto I, et al. Sci Rep. 2022 Feb 7;12(1):2025. doi: 10.1038/s41598-022-06084-z. Sci Rep. 2022. PMID: 35132165 Free PMC article.

10

Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.

Huang Z, Zheng S, Ding S, Wei Y, Chen C, Liu X, Li H, Xia Y. Huang Z, et al. J Cancer Res Ther. 2021 Jul;17(3):676-687. doi: 10.4103/jcrt.JCRT_1606_20. J Cancer Res Ther. 2021. PMID: 34269299 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

145 results

Results by year